Compare Lufax Holding Ltd (LU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Lufax Holding Ltd trades at $0.98 (market cap $982.89M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 17.2× Lufax Holding Ltd's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LU | ZBH | |
|---|---|---|
Market Cap | $982.89M | $16.95B |
Volume | 3,323,384 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $3.78 | $103.98 |
52-Week Low | $0.95 | $79.58 |
Typical Hold Time | 13 Days | 89 Days |
Enterprise Value | $58.81B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $0.95, down 3.54% on the day, with a bearish technical signal from moving averages but a bullish oscillator reading. The company reported a net loss of $2.10 billion in 2025 on revenue of $23.11 billion, with negative net income margins and ROE. A 10:1 reverse stock split occurred on October 23, 2026, and recent news highlights regulatory challenges and balance sheet strength.
The outlook remains challenged by persistent losses and revenue declines, though deep value is suggested by a P/B of 0.07 and strong parent backing. Risks include regulatory tightening in China and elevated credit costs, but analyst consensus is 69% buy with potential catalysts from capital return events.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
